ANTITUMOR-ACTIVITY, GROWTH, AND PHENOTYPE OF LONG-TERM IL-2 CULTURES OF HUMAN NK AND LYMPHOCYTES-T

被引:0
作者
FUCHSHUBER, PR [1 ]
LOTZOVA, E [1 ]
POLLOCK, RE [1 ]
机构
[1] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT GEN SURG,NAT IMMUN SECT,HOUSTON,TX 77030
来源
LYMPHOKINE AND CYTOKINE RESEARCH | 1991年 / 10卷 / 1-2期
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have studied growth, function, and phenotype of purified NK and T cells in long-term cultures and compared these parameters to those of conventionally prepared interleukin-2-activated lymphocytes with killer cell activity (LAK). Enrichment of NK and T cells was achieved by Percoll density gradient. Growth was analyzed by cell counts and [H-3]TdR uptake. Cytotoxicity and tumor-binding efficacy were assessed in a 3-h Cr-51 and single cell agarose assay, respectively, against K-562, Daudi, human ovarian cell line Ovcar-3, and fresh leukemic blasts. We found that long-term proliferation and lytic activity were highest in NK-enriched and lowest in T-enriched cultures. Conventional LAK cultures generated medium cytotoxicity levels. Lytic activity declined within 3 weeks in cultures not enriched for NK cells, while NK-enriched cultures showed high levels of cytotoxicity up to 6 weeks. No change was found in binding activity within 3 weeks with the exception of T cell-enriched fraction. A number of changes in the phenotypic patterns was observed in IL-2 cultures; the CD56+/CD3-/+ and CD56+/CD8+ subset increased in most cultures, whereas the CD56-/CD3+ subset decreased over time. The highly enriched NK cell culture maintained its NK cell phenotype over 5-6 weeks. We also delineated the most cytotoxic lymphocyte subset in long-term IL-2 cultures by complement dependent cytotoxic assays and fluorescence-activated cell sorting (FACS). Lytic activity in conventional LAK as well as in T and NK cell-enriched IL-2 cultures was mediated primarily by CD56+, CD16+, CD3- NK cells. The clinical implication of these studies is discussed.
引用
收藏
页码:51 / 59
页数:9
相关论文
共 29 条
  • [1] DIXON WJ, 1982, BMDP BIOMEDICAL COMP
  • [2] LYMPHOKINE-ACTIVATED KILLER CELL PHENOMENON - LYSIS OF NATURAL KILLER-RESISTANT FRESH SOLID TUMOR-CELLS BY INTERLEUKIN 2-ACTIVATED AUTOLOGOUS HUMAN PERIPHERAL-BLOOD LYMPHOCYTES
    GRIMM, EA
    MAZUMDER, A
    ZHANG, HZ
    ROSENBERG, SA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 155 (06) : 1823 - 1841
  • [3] LYMPHOKINE - ACTIVATED KILLER CELL-ACTIVITY - CHARACTERISTICS OF EFFECTOR-CELLS AND THEIR PROGENITORS IN BLOOD AND SPLEEN
    HERBERMAN, RB
    HISERODT, J
    VUJANOVIC, N
    BALCH, C
    LOTZOVA, E
    BOLHUIS, R
    GOLUB, S
    LANIER, LL
    PHILLIPS, JH
    RICCARDI, C
    RITZ, J
    SANTONI, A
    SCHMIDT, RE
    UCHIDA, A
    [J]. IMMUNOLOGY TODAY, 1987, 8 (06): : 178 - 181
  • [4] HERBERMAN RB, 1989, J CLIN ONCOL, V7, P1
  • [5] ITOH K, 1985, J IMMUNOL, V134, P802
  • [6] LOTZE MT, 1981, CANCER RES, V41, P4420
  • [7] HIGH-DOSE RECOMBINANT INTERLEUKIN-2 IN THE TREATMENT OF PATIENTS WITH DISSEMINATED CANCER - RESPONSES, TREATMENT-RELATED MORBIDITY, AND HISTOLOGIC-FINDINGS
    LOTZE, MT
    CHANG, AE
    SEIPP, CA
    SIMPSON, C
    VETTO, JT
    ROSENBERG, SA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (22): : 3117 - 3124
  • [8] ANALYSIS OF EFFECTOR MECHANISMS IN CANCER
    LOTZOVA, E
    [J]. CURRENT OPINION IN IMMUNOLOGY, 1989, 1 (05) : 904 - 909
  • [9] LOTZOVA E, 1989, MED ONCOL TUMOR PHAR, V6, P93
  • [10] RECOMBINANT IL-2-ACTIVATED NK CELLS MEDIATE LAK ACTIVITY AGAINST OVARIAN-CANCER
    LOTZOVA, E
    SAVARY, CA
    FREEDMAN, RS
    EDWARDS, CL
    WHARTON, JT
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1988, 42 (02) : 225 - 231